Progress in pharmacotherapy of pulmonary arterial hypertension in children.
- Author:
Yan-Ping YU
1
;
Xian-Mei HUANG
Author Information
1. Department of Pediatrics, First People's Hospital of Hangzhou, Hangzhou 310006, China. yyp757605@163.com
- Publication Type:Journal Article
- MeSH:
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine;
analogs & derivatives;
therapeutic use;
Calcium Channel Blockers;
therapeutic use;
Child;
Epoprostenol;
analogs & derivatives;
therapeutic use;
Familial Primary Pulmonary Hypertension;
Humans;
Hypertension, Pulmonary;
diagnosis;
drug therapy;
Iloprost;
therapeutic use;
Sulfonamides;
therapeutic use
- From:
Chinese Journal of Contemporary Pediatrics
2012;14(3):236-240
- CountryChina
- Language:Chinese
-
Abstract:
This paper provides an overview of the current state of pharmacotherapy in children with pulmonary arterial hypertension (PAH) and a brief introduction to the potentially novel pharmacologic targets for PAH. Currently, 3 classes of drugs including prostacyclin analogues, endothelin receptor antagonists and phosphodiesterase-5 inhibitors are approved for the treatment of PAH in children, which has led to improved hemodynamics, increased exercise capacity and prolonged survival. Despite these improvements, there is still a need to carry out well-designed, randomized, controlled studies with larger samples. In addition, novel drugs targeting other molecular pathways should be developed.
